Sheila Gujrathi's Net Worth
$11.3 Million
Who is Sheila Gujrathi?
Sheila Gujrathi has an estimated net worth of $11.3 Million. This is based on reported shares across multiple companies, which include Turning Point Therapeutics, Inc., Receptos, Inc., Ventyx Biosciences, Inc., Gossamer Bio, Inc., Janux Therapeutics, Inc., and FIVE PRIME THERAPEUTICS INC.
SEC CIK
Sheila Gujrathi's CIK is 0001575202
Past Insider Trading and Trends
2019 was Sheila Gujrathi's most active year for acquiring shares with 4 total transactions. Sheila Gujrathi's most active month to acquire stocks was the month of May. 2015 was Sheila Gujrathi's most active year for disposing of shares, totalling 5 transactions. Sheila Gujrathi's most active month to dispose stocks was the month of July. 2023 saw Sheila Gujrathi paying a total of $603,000.00 for 128,437 shares, this is the most they've acquired in one year. In 2015 Sheila Gujrathi cashed out on 344,645 shares for a total of $44,119,054.22, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Turning Point Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Receptos, Inc. No price found
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -133.16K |
—
|
—
|
0
|
Aug 25 - Aug 27
| |||
Form 4
| +10.36% | 12.5K |
—
|
—
| 133.16K |
Apr 1
| |||
Form 4
| -19.91% | -30.00K |
$108.99 | -$3,269,700.00 | 120.66K |
Scheduled
|
Nov 11
| ||
Form 4
| -16.61% | -30.00K |
$61.45 | -$1,843,500.00 | 150.66K |
Scheduled
|
Sep 22
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 17
| |||
Form 4
| +7.97% | 13.33K |
$5.25 | $69,998.25 | 180.66K |
May 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ventyx Biosciences, Inc. (VTYX) Snapshot price: $2.34
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
$19.88 | -$2,770,240.00 |
0
|
Mar 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 2
| |||
Form 4
|
∞
| 32.9K |
—
|
—
| 32.9K |
Oct 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Gossamer Bio, Inc. (GOSS) Snapshot price: $0.87
President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 189.5K |
—
|
—
| 189.5K |
Feb 14
| |||
Form 4
| +0.25% | 10K |
$16.80 | $167,980.00 | 4.05M |
Sep 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 25
| |||
Form 4
| +1.56% | 62.03K |
—
|
—
| 4.04M |
Feb 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Janux Therapeutics, Inc. (JANX) Snapshot price: $8.88
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +2.31% | 2.5K |
—
|
—
| 110.53K |
Jun 26
| |||
Form 4
| +2.84% | 2.99K |
—
|
—
| 108.03K |
Feb 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||